## Zhikai Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/275609/publications.pdf

Version: 2024-02-01

933447 888059 27 314 10 17 h-index citations g-index papers 33 33 33 367 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	A blind randomized validated convolutional neural network for autoâ€segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy. Cancer Medicine, 2022, 11, 166-175.	2.8	12
2	Risk of second primary malignancies associated with radiotherapy in prostate cancer patients: competing risk analysis. Future Oncology, 2022, 18, 445-455.	2.4	3
3	Perceived quality of care and its associated factors among Chinese patients with advanced cancer: findings from the APPROACH study in Beijing. Supportive Care in Cancer, 2021, 29, 1395-1401.	2.2	2
4	Outcome of Non-small Cell Lung Cancer Patients With N3 Stage: Survival Analysis of Propensity Score Matching With a Validated Predictive Nomogram. Frontiers in Surgery, 2021, 8, 666332.	1.4	3
5	The Impact of Different Simulation Modalities on Target Volume Delineation in Breast-Conserving Radiotherapy. Cancer Management and Research, 2021, Volume 13, 5633-5640.	1.9	O
6	An Adversarial Deep-Learning-Based Model for Cervical Cancer CTV Segmentation With Multicenter Blinded Randomized Controlled Validation. Frontiers in Oncology, 2021, 11, 702270.	2.8	7
7	Second primary malignancies associated with radiation therapy in cervical cancer patients diagnosed between 1975 and 2011: a population-based competing-risk study. Annals of Translational Medicine, 2021, 9, 1375-1375.	1.7	6
8	Long-term radiation therapy-related risk of second primary malignancies in patients with lung cancer. Journal of Thoracic Disease, 2021, 13, 5863-5874.	1.4	5
9	Second Malignant Neoplasms in Patients With Rhabdomyosarcoma. Frontiers in Oncology, 2021, 11, 757095.	2.8	2
10	Automatic Segmentation of Clinical Target Volume and Organs-at-Risk for Breast Conservative Radiotherapy Using a Convolutional Neural Network. Cancer Management and Research, 2021, Volume 13, 8209-8217.	1.9	10
11	Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database. Radiation Oncology, 2021, 16, 228.	2.7	4
12	A Population-Based Systematic Clinical Analysis With a Single-Center Case Series of Patients With Pulmonary Large Cell Neuroendocrine Carcinoma. Frontiers in Endocrinology, 2021, 12, 759915.	3.5	1
13	Segmentation of organs-at-risk in cervical cancer CT images with a convolutional neural network. Physica Medica, 2020, 69, 184-191.	0.7	68
14	Development and validation of a deep learning algorithm for auto-delineation of clinical target volume and organs at risk in cervical cancer radiotherapy. Radiotherapy and Oncology, 2020, 153, 172-179.	0.6	51
15	Prognostic outcome after second primary lung cancer in patients with previously treated lung cancer by radiotherapy. Journal of Thoracic Disease, 2020, 12, 5376-5386.	1.4	3
16	Outcome of multidisciplinary treatment of peripheral primitive neuroectodermal tumor. Scientific Reports, 2020, 10, 15656.	3.3	6
17	COVID-19 outbreak and cancer patient management: Viewpoint from radio-oncologists. Radiotherapy and Oncology, 2020, 149, 44-45.	0.6	6
18	Abscopal effect induced by modulated radiation therapy and pembrolizumab in a patient with pancreatic metastatic lung squamous cell carcinoma. Thoracic Cancer, 2020, 11, 2014-2017.	1.9	7

## Zhikai Liu

#	Article	IF	CITATION
19	Neoadjuvant chemoradiotherapy or radiotherapy in patients aged 75 years or older with locally advanced rectal cancer. Journal of Cancer, 2020, 11, 3536-3542.	2.5	2
20	Automatic Segmentation of Clinical Target Volumes for Post-Modified Radical Mastectomy Radiotherapy Using Convolutional Neural Networks. Frontiers in Oncology, 2020, 10, 581347.	2.8	14
21	Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. Gynecologic Oncology, 2019, 155, 224-228.	1.4	15
22	Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification. Radiation Oncology, 2019, 14, 228.	2.7	16
23	Treatment outcomes of intracranial germinoma: a retrospective analysis of 170 patients from a single institution. Journal of Cancer Research and Clinical Oncology, 2019, 145, 709-715.	2.5	23
24	Escalated radiation and prophylactic extended field nodal irradiation are beneficial for FIGO IIIB cervical cancer patients' prognosis. Radiation Oncology, 2018, 13, 223.	2.7	11
25	How much margin do we need for pelvic lymph nodes irradiation in the era of IGRT?. Journal of Cancer, 2018, 9, 3683-3689.	2.5	7
26	Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer. Oncotarget, 2017, 8, 102965-102973.	1.8	19
27	Low-Dose-Area-Constrained Helical TomoTherapy-Based Whole Breast Radiotherapy and Dosimetric Comparison with Tangential Field-in-Field IMRT. BioMed Research International, 2013, 2013, 1-6.	1.9	10